News Hub | News Direct

Cohen Institute Mental Health Conference in Evanston to Focus on Managing Stress

The Chicago School of Professional Psychology

The Naomi Ruth Cohen Institute for Mental Health Education (NRCI) at The Chicago School of Professional Psychology (TCSPP) will bring together the community and professionals on June 10, 2023 to discuss "Untying the Human Knot: Managing Stress & Anxiety in Today's World." The conference is set for 9:30am-3:30pm at Evanston Township High School (1600 Dodge Ave., Evanston, Ill., 60201). Registration is available at the door. The 90-minute opening panel presentation features Gabriela Diaz, Orson Morrison, PhD, and Paula R. Young, PhD, ACT. The panel will be moderated by Michael Horowitz, PhD, President of The Community Solution Education System. The panel will be followed by three rounds of professional-led breakout sessions as well as a post-event networking session. Lunch is included. Gabriela Diaz is a Chicago-based actor, teaching artist, and mental health advocate. She received her BFA at Webster University’s Leigh Gerdine College of Fine Arts. She has worked with The Art Institute, Steppenwolf Theatre, Firebrand Theatre, Jackalope Theatre, and others. Gabriela has found a creative home at Erasing The Distance (ETD), where she combines her passion for the arts and mental health. As a person living with anxiety, Gabriela finds immense joy in sharing her story to spark dialogue about the human experience. Orson Morrison, PhD, is a licensed clinical psychologist and the co-owner of LifeSpan Counseling and Psychological Services. He is also the Associate Director of Clinical Services for DePaul University Counseling & Psychological Services. He has worked in a variety of clinical settings including college counseling centers, community mental health centers, medical settings, private practice, and in academic-clinical research units. His professional interests and areas of expertise include psychotherapy with children, adolescents, adults, and families; racial and intergenerational trauma; psychological assessment; and contemplative practices. Paula R. Young, PhD, ACT, is a licensed clinical psychologist and senior clinical director at Rogers Behavioral Health. There, she leads the clinicians who are focused on adolescent and adult mental health. Dr. Young, who received her doctorate from Finch University of Health Sciences/The Chicago Medical School, has extensive experience working with those with depression and anxiety disorders. She has presented to numerous clinical and academic audiences across the country. Michael Horowitz, PhD, is the President of The Community Solution Education System. Dr. Horowitz leads The Community Solution and its system of nonprofit colleges and universities including The Chicago School of Professional Psychology (TCSPP). Dr. Horowitz received his Ph.D. in Clinical Psychology from Northwestern University in 1986. The professional-led breakout sessions include informative presentations on topics like managing stress and anxiety at different stages of one’s life, building resilience, developing healthy coping mechanisms, and other topics. The conference is open to all community members and offers CEUs to licensed mental health and other professionals. Tickets will be available for $45 (with an added $25 for those seeking CEUs). Partial and full scholarships are available. Since 2002, NRCI has hosted an annual community mental health conference in Evanston, Ill., to bring together those with lived experience, their caregivers, supporters, and treatment professionals as well as members of the community interested in learning more about a specific mental health challenge or issue. NRCI is committed to providing mental health education and training in the Chicagoland area, and reducing the stigma often associated with mental health challenges and suicide, a cause the organization’s founders, Larry and Marilyn Cohen, embraced after their daughter Naomi died by suicide after living with bipolar disorder. About The Chicago School of Professional Psychology: Integrating theory with hands-on experience, The Chicago School of Professional Psychology provides education rooted in a commitment to innovation, service, and community for thousands of diverse students across the United States and globally. Founded in 1979, the nonprofit, regionally accredited university now features campuses in iconic locations across the country (Chicago, Southern California, Washington, D.C., New Orleans, Dallas) and online. To spark positive change in the world where it matters most, The Chicago School has continued to expand its educational offerings beyond the field of psychology to offer more than 30 degrees and certificates in the professional fields of health services, education, counseling, business, and more. Through its engaged professional model of education, commitment to diversity and inclusion, and an extensive network of domestic and international professional partnerships, The Chicago School’s students receive real-world training opportunities that reflect their future careers. The Chicago School is proud to be a part of TCS Education System, a nonprofit, integrated system of colleges and universities that works collaboratively to advance student success and community impact. To learn more, visit www.thechicagoschool.edu. Contact Details Vivien Hao +1 323-893-4743 vhao@thechicagoschool.edu

June 01, 2023 12:00 PM Eastern Daylight Time

Galexxy Holdings Inc., Appoints High Profile Chief Marketing Officer

GALEXXY HLDGS INC.

Galexxy Holdings Inc., (“Galexxy” or “Company”) (OTC: GXXY) is pleased to advise that it has appointed Dan Gay as its Chief Marketing and Sales Officer. Dan has a very successful background as a senior marketing and sales executive, adept at creating new markets, forming strategic sales alliances, and developing rapid growth of sales revenue. Dan’s early background includes senior positions with MCI Telecom (200 employees increased to 30,000 during his tenure), and Qwest, which grew to a $60 billion company. At MCI he managed sales teams in a 15-state region, which led national sales by adding $115m in new revenues. He became one of the highest-producing regions in the U.S. Dan also created and managed a 450-employee outreach Call Center, increasing MCI’s client base by 420,000 customers. At Qwest, Dan transformed an underperforming division to surpass plan and was chosen for the executive team that acquired and integrated the $44 billion US West telephone company. Dan was appointed Vice President and Chief Marketing Officer (CMO) of iThrive Health (2010-2017) a consortium targeting physicians and consumers with proprietary software offering 10,000-plus health products. Dan increased online revenues by 315%, grew the client base by 500%, and expanded SKUs six-fold. He also negotiated joint partnerships and led the successful acquisition of a related products company. More recently, in 2018 Dan was appointed Chief Marketing and Sales Officer of a leading blockchain growth company with employees and partner channels on 6 continents. As a member of the senior executive team, he tripled sales growth in 2022, brought 9 new products to market with thousands of daily downloads, and negotiated millions in angel investments. Galexxy’s CEO, Michael Biagi stated that; “Dan has the motivation and innovative expertise to build important strategic partnerships and drive our revenue growth to enable us to up-list onto NASDAQ”. Galexxy is headquartered in Newport Beach and its shares are publicly traded on the OTC Markets (OTC: GXXY). Galexxy entered the rapidly developing markets for premium natural plant-based health supplements and superfoods in April 2021, and completed its acquisition of Wellbeing Farms LLC., on August 4, 2022, and purchased 69% of ABC Wholesale Products LLC., on August 12, 2022. Galexxy Holdings Inc. CEO Michael Biagi E: Michael@galexxyholdings.com M: (801) 243 9570 Forward-Looking Information This press release contains “forward-looking information” and “forward-looking statements” (collectively, “statements”). All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this press release. www.galexxyholdings.com www.wellbeingfarms.com https://twitter.com/GXXYHoldings Contact Details Galexxy Holdings Inc. Michael@galexxyholdings.com

June 01, 2023 10:00 AM Eastern Daylight Time

News Release

Breaking News: WriteMyEssays And WriteMyPapers Merge. Learn More Here!

Halvorson Media Group

Recently, WriteMyEssays And WriteMyPapers signed a merger agreement. Find out what to expect from the changes, whether they will affect customers, and what new features are planned to be introduced. New York, May 28, 2021 — A few days ago, an academic writing company WriteMyEssays announced the acquisition of WriteMyPapers. This decision has been discussed for several months, and finally, there was official confirmation of the merger. Due to the inability to compete with other academic services, the WriteMyPapers brand decided to leave the market. In the past few months, the site has seen a surge in orders, and the staff has been unable to keep up with the influx. The departure of the company would have suffered great losses and the loss of valuable personnel. Thus, the decision to merge was the only correct one in this situation. The management bodies have already checked and approved the terms and conditions of the upcoming merger. What to Expect from The Merger? A merger is a complex business solution that takes time to set up internal processes. Of course, the company's management is going to consolidate high-quality academic writing in the industry and enter the international market. However, no one excludes the occurrence of difficulties, but first things first. At the moment, key stakeholders of both companies discussed several business benefits which can be expected in the near term. They are obvious, but are of great benefit to the company: Increasing the staff of the company. The staff of WriteMyPapers was more than 300 people. All writers pass under the control of the new owner. Thus, it means that the service will be able to process more orders and get more urgent assignments. Increasing the audience. Those customers who previously applied to WriteMyPapers are likely to start ordering essays and other assignments from a new company. Many students have been working with the same authors for several years, and they will be able to continue doing this under a new brand. Increasing monthly turnover. The more orders, the more income. This is a simple yet complex business rule. If the quality of the work performed remains at the same high level or becomes higher, the company will be able to increase income by 2-3 times. Moreover, this is a very significant indicator in the college writing industry. In the long term, the company expects the following positive changes: Entering the international market. In connection with scaling, it is planned to introduce new working languages. The managing department has ideas for covering European countries, China, and India. This will expand the audience by 5-6 times in the long run. Building a multi-level support system. Due to the increase in the audience, support representatives will need to be divided into several categories depending on the purpose: support for resolving payment issues, support for placing orders, support for submitting changes to orders, etc. Development of services in narrow areas. In a rapidly evolving environment, it is necessary to follow education trends. That is a real challenge to find specialists in AI engineering or bioinformatics with academic writing or teaching skills. However, this must be taken into account in order to be at the top of the best services. What Do The Experts Say? “The decision to merge was nothing short of a bold one for us. We expect to see results in two months. However, despite the encouraging results in the future, we understand that at first, the team may experience difficulties. Talks about a merger started early this year and we've more or less solidified the base to weather this challenging but promising time.” Harry Evans, WriteMyEssays Vice President “Our department will be the most heavily loaded, especially at the very start. We have developed an order distribution system that should help us not only cope with the number of incoming orders but also understand our strengths and weaknesses to improve the process. The scaling steps will be introduced smoothly, and we know we can adjust to new circumstances.” Emma Walker, Order Distribution Manager “We are pleased with the new changes and are ready to scale and introduce new services. Thanks to long-term planning and quick reaction to possible strategic changes, our company is moving into a higher orbit. We can call ourselves a company providing educational assistance services.” Caleb Ellington, Senior Manager About WriteMyEssays WriteMyEssays is an academic writing company that has been on the market for over 15 years. The company operates in the field of educational services, namely in writing papers of various formats for high school, college, and university students. The emphasis on "academic" demonstrates high standards of performance. At the moment, the company provides assistance in the following areas: academic writing, proofreading & editing, and problem-solving. These three services fully cover the needs of a broad student audience. The team assists with handling assignments of different levels: High School, Undergraduate, Bachelor, Master, and Professional. The company works in various fields: Mathematics, Literature, Chemistry, Architecture, Pharmacology, Law, and more than 30 other areas of study. The support service has every opportunity to select a performer with the appropriate education and academic writing skills. The list of services includes not only writing essays, but also making presentations, creating graphs and tables, writing speeches, typing, rewriting, performing mathematical calculations, helping with writing dissertations, conducting chemical, historical, mathematical, and literary analyzes, and much more. WriteMyEssays is often the choice of students due to the loyal pricing policy. Thanks to successful management and logistics, prices for services are kept below average. It allows students with a limited budget to place orders on the site. The company also often provides discounts and loyalty programs. With over 7,000 finished assignments, WriteMyEssays is one of the leaders in the professional student assistance industry. Most likely, new changes will lead this service to new achievements and the introduction of new services that meet the passage of time. On a Final Note The goal of the WriteMyEssays company is to remain competitive, gradually expanding the list of services, introducing new payment methods, and taking other equally important steps to be on top. The field of academic education is entering challenging times. It may not yet be obvious, but companies like WriteMyEssays will take on an inflated amount of workload to save education as a basic social sphere from a great collapse Contact Details Halvorson Media Group Edward +1 877-422-8205 edward@halvorsonmediagroup.com Company Website https://halvorsonmediagroup.com/

June 01, 2023 09:52 AM Eastern Daylight Time

Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?

OKYO Pharma

By David Willey, Benzinga The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio (NASDAQ: ISEE). Iveric Bio’s focus is on developing innovative treatments for eye diseases. Through the purchase, Astellas has signaled it will be sharpening its focus in the field of ‘blindness and regeneration’. The price for the acquisition was set at $5.9 billion, and following the news Iveric’s stock (ISEE) rose 17.9% to $38.79. The global ophthalmology market was worth $33.56 billion in 2022 and is predicted to reach $54.87 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.4% during the forecast period. A trend in the market is toward finding novel treatments and innovative drug delivery systems, and this trend is driving research in the sector. A second recent major acquisition in the sector was Viatris, Inc. ’s (NASDAQ: VTRS) acquisition of Oyster Point Pharma and Famy Life Sciences at the beginning of the year. The acquisition, for a combined $695 million, allowed the global healthcare company to establish Viatris Eye Care Division. Dry Eye Disease And OKYO A range of ocular diseases, like glaucoma, uveitis and retinal diseases are most prevalent in the geriatric population, and rates of disease are increasing as the population ages. One of the most common ocular diseases is dry eye disease (DED). It affects almost 50 million people in the US, and the global market for DED was worth $4.5 billion in 2022. It is predicted to reach $6.3 billion by 2028, at a compound annual growth rate (CAGR) of 5.67% during the forecast period. OKYO Pharma Ltd. (NASDAQ: OKYO) is a biopharma leading the way when it comes to developing novel treatments for DED and ocular pain. Founded in 2018, the company was able to bypass phase 1 safety trials and has begun screening patients for its phase 2 efficacy trials. The trial includes 240 patients, and OKYO anticipates having topline data on its drug, OK-101, in Quarter 4 of 2023. OK-101 uses a novel chemerin receptor that both acts as an anti-inflammatory agent and reduces corneal neuropathic pain in the patient. As the treatment is administered topically as eye drops, there is almost no risk of systemic exposure or risk of the treatment getting into the bloodstream. If the trial meets its pre-specified endpoints, this could contribute data toward registration trials, and speed up OK-101’s timeline for approval from the Food and Drug Administration (FDA). The company is laser-focused on bringing its treatment to market, as it believes the treatment has significant potential in the sector. With recent acquisitions indicating a commitment from big biopharmaceuticals to the ophthalmology market, there may be many eyes watching the progress of OKYO’s phase 2 trials. Keep up with OKYO’s developments in the eye care market on its website. OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR christine@tradigitalir.com Company Website https://okyopharma.com/

June 01, 2023 09:00 AM Eastern Daylight Time

Leidos Becomes First Major Prime Contractor to Adopt NCMA Contract Management Standard

National Contract Management Association

Leidos (NYSE: LDOS), a FORTUNE® 500 science and technology leader, today announced its intent to adopt the National Contract Management Association’s (NCMA) Contract Management Standard ™ (CMS™). By adopting this standard, Leidos will align its workforce competency with the standard recently adopted by the federal government and institutions of higher education. With this adoption, Leidos builds on its long-standing commitment to strong customer relationships through standards of professional conduct and common understanding. The company is committed to developing the contract management profession as a meaningful and rewarding career path. This will support practitioners across industry and government who serve the federal mission. “Leidos Contracting is excited to lead the industry in the adoption of the CMS™,” said Kim Denver, Leidos Senior Vice President and Chief Corporate Contracts Executive. “Contract management professionals are paramount to mission success. Through the CMS framework, our tradecraft will be incorporated under one common standard, elevating both federal and industry contract management professionals who are critical to our nation’s success.” “NCMA is pleased to have Leidos join the growing community of CMS™ adopters dedicated to building a stronger bridge between industry and government,” said NCMA Chief Executive Officer Kraig Conrad. “This adoption reinforces Leidos' commitment to the profession; their contract management teams and the missions we serve together.” The U.S. Office of Federal Procurement Policy (OFPP) announced the new classification in a January 19 memo, stating that the CMS™ will become the foundation of a new contracting training system for all civilian agencies effective February 1, 2023. The new Federal Acquisition Certification in Contracting (FAC-C) (Professional) will now align with the Department of Defense framework (DAWIA), which is also based on the CMS™. The American National Standards Institute (ANSI)-approved third edition of the NCMA CMS™ is recognized globally as the preeminent standard in the profession. It serves as the basis for hiring and training frameworks as well as the NCMA’s ANSI National Accreditation Board (ANAB)-accredited Certified Contract Management Associate (CCMA) certification. The National Contract Management Association (NCMA), which was founded in 1959 and is the world’s leading association in the field of contract management. The organization, which has over 18,000 members, is dedicated to the professional growth and educational advancement of procurement and acquisition personnel worldwide. NCMA strives to serve and inform the profession and industry it represents and to offer opportunities for the open exchange of ideas in neutral forums. To find out more, please visit www.ncmahq.org. About Leidos Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, civil, and health markets. The company’s 45,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $14.4 billion for the fiscal year ended December 30, 2022. For more information, visit www.Leidos.com. ### Certain statements in this announcement constitute “forward-looking statements” within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements are based on management’s current beliefs and expectations and are subject to significant risks and uncertainties. These statements are not guarantees of future results or occurrences. A number of factors could cause our actual results, performance, achievements, or industry results to be different from the results, performance, or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, the “Risk Factors” set forth in Leidos’ Annual Report on Form 10-K for the fiscal year ended December 30, 2022, and other such filings that Leidos makes with the SEC from time to time. Readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Leidos does not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the date the forward-looking statements were made. Contact Details NCMA Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org/

June 01, 2023 07:55 AM Eastern Daylight Time

News Release

Mangoceuticals Inc. (NASDAQ: MGRX) and the Booming Men's Health Market

CapitalGainsReport

The men's health sector is ripe with potential, offering attractive opportunities as companies meet the growing demand for male-centric wellness solutions. Recent market research projects a staggering compound annual growth rate (CAGR) of 15.00% by 2029, signaling substantial potential for investors. A confluence of factors, including a rise in men's health awareness, a paradigm shift in societal norms that emphasize self-care, and ground-breaking developments in medical technology and research, are just a few of the factors driving the growth in this sector. The Market The men's health market encompasses a diverse range of products and services, including pharmaceuticals, dietary supplements, fitness equipment, personal care products, telehealth services, and tailored wellness programs. These offerings cater to various aspects of men's health, including physical fitness, mental wellness, and nutritional support. Mangoceuticals, Inc. (NASDAQ: MGRX) MGRX is an emerging company that specializes in developing, marketing, and selling cutting-edge men's health and wellness products. Through their secure telemedicine platform called 'MangoRx,' they provide convenient access to their flagship product, Mango—an innovative medication specifically designed to treat the symptoms of erectile dysfunction (ED). IPO MangoRx recently concluded its successful IPO on the Nasdaq Capital Market, generating $5,000,000 in gross proceeds. These funds will be utilized to finance marketing and operational expenses related to the planned launch of their flagship Mango product. Additionally, the proceeds will support talent acquisition, software development, and general corporate purposes. Mangoceuticals is making waves in the men's health market with its innovative approach and commitment to redefining the standards for ED treatment. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. The MGRX Approach Beyond product offerings, Mangoceuticals understands the importance of education and information in men's health. MangoRx is dedicated to providing comprehensive knowledge and resources, empowering men to make informed decisions about their well-being. By sharing information confidently and breaking down barriers, Mangoceuticals is destigmatizing the conversation around men's health. MangoRx offers a convenient telemedicine platform, allowing men to access their products without leaving their homes. By eliminating the need for in-person doctor visits, MangoRx provides a discreet and accessible solution for men's health needs. With a streamlined process, users can create an account, complete a telemedicine session, and have their prescribed products delivered to their doorstep. The MangoRx approach differs from other ED treatments in its commitment to education and refreshing approach to the topic. While the subject matter is serious, MangoRx embraces a fun and confident attitude. By injecting humor into their brand, they aim to empower men on their journey to better health, ensuring that the pursuit of 'intimate well-being' is an enjoyable experience. Mango (Man-Go) Mango, Mangoceuticals' flagship product, is a groundbreaking solution designed to address men's unique concerns. Unlike many competitors offering generic medications, Mangoceuticals takes pride in creating its own expertly formulated ED compounds, ensuring a superior experience for customers. Crafted with FDA-approved ingredients, Mango combines a selection of compounds to target the challenges men face in intimate situations. Mango stands out with its rapid-dissolving mango-flavored tablets, which deliver quicker results by efficiently entering the bloodstream. These sublingual Rapid Dissolving Tablets (RDTs) contain the same active ingredient as Cialis (tadalafil), as well as the MGRX unique blend. By incorporating this combination, Mango offers a tasty, efficient, and powerful solution for men seeking faster relief from the symptoms of ED. Earlier this month, MGRX announced via Twitter that Mango is now available in Nevada. This expansion marks a significant milestone for Mangoceuticals as they continue to broaden their market reach and offer their cutting-edge men's health and wellness products to new potential customers. Mango is now available in 44 states, including Nevada and the District of Columbia. Looking Ahead With its focus on innovation, education, and maintaining a fun and confident approach, MGRX could make a significant impact in the men's health market. They provide men with the tools and resources they need to prioritize their well-being and enhance their overall quality of life. CapitalGainsReport is a financial website for investors seeking nanocap and microcap commentary. We cover macroeconomic news, sector plays, company news, technical analysis, market action alerts, and catalysts that may potentially drive price action. To join our newsletter, read the most recent stories, and review our disclaimer please visit our site at CapitalGainsReport.com Disclaimers: CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport 'CGR' is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by CGR or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. CapitalGainsReport is not a fiduciary by virtue of any persons use of or access to this content. Contact Details CapitalGainsReport Mark McKelvie +1 585-301-7700 markrmckelvie@gmail.com Company Website http://CapitalGainsReport.com

June 01, 2023 05:00 AM Eastern Daylight Time

RemSleep Holdings Inc. Provides a Corporate Update and Correction

RemSleep Holdings, Inc.

RemSleep Holdings Inc. (OTCQB: RMSL), a medical device manufacturer dedicated to forever changing the level of treatment provided to Obstructive Sleep Apnea (OSA) patients, provides an update on its testing protocol for 510K clearance of its DeltaWave CPAP Mask as well as a correction on previous update on the Cytotoxicity testing. It was previously announced the Cytotoxicity test was restarted due to contamination. That statement was incorrect. The Cytotoxicity test was started significantly later than was originally communicated to RemSleep and was scheduled to be completed mid to late May. The MLA (Mouse Lymphoma Assay) test was the test which experienced the contamination that had to be restarted once the contamination was identified and deemed to potentially compromise test results. The mid to end of May timeline remained valid for testing completion. About a week ago, RemSleep was informed that the MLA test had once again shown signs of contamination towards the end of the test. The test sample was disposed of before RemSleep could determine the source, or origin of the contamination. At that time, rerunning the test would not represent a material shift in the timeframe due to the Cytotoxicity test starting later than what had previously been communicated to the company. This time, due to the second issue of contamination and remaining tests being completed, the sample was isolated and it was determined the contamination was from mold. Due to the nature of the testing, it is extremely difficult to locate the source of mold contamination. Furthermore, due to the nature of mold, it can develop quickly, whereas with this test it was found near the end and may have developed about midway through the test. Both MLA tests were run by a contracted lab through our primary lab partner. This is due to our primary lab not having the equipment to run this specific test. This is one of two tests that were contracted to outside labs. It is critical to note that the remaining tests have all been run through our primary lab and there have been no contamination or handling issues in any other tests in the protocol. As previously noted, RemSleep went through a strict protocol in preparing the DeltaWave samples for this testing which involved preparing them in a clean room, sterile environment. Additional samples have been prepared for retesting and the company has taken an additional step of shrink wrapping the entire sample prior to shipping to ensure no contamination can be derived from the handling during the shipping process. FDA protocol directs the testing lab to test the unit in question directly from the packaging without any modification, cleaning, sterilization, etc. While RemSleep is confident the precursor to the mold development did not come from handling in the sample preparation at the company facility with the prior samples, this additional abundance of caution was taken to further rule out any possible source of contamination while the Deltawave was in company hands. The Deltawave itself has passed all tests with no issues, so at the end of the day we know Deltawave will get past testing, of which there was never any doubt from the beginning. There was significant discussion about the impact the mold contamination had on the actual test results and moving forward with the MLA results for submission despite the contamination. In the end, there is no way to conclusively prove the mold contamination had no material affect (positive or negative) on the test results and the company was advised to rerun the test. While this will once again delay 510K submission, the successful test results minus the contamination issue validates the company’s assertion and/or belief that the DeltaWave is inherently safe due to the materials used. Along those lines, the company wants to iterate in no uncertain terms that all materials used in the design and manufacture of the DeltaWave device are Class VI Medical Grade and these materials are used safely by millions of Americans every day in FDA cleared devices throughout the US. The company has prepared the new samples as noted above and have been shipped to the testing lab, which will be received by the testing lab 6/1/2023. The company has been assured the new test will take priority and will not be put into a que to start on a later date, which happened previously (with the Cytotoxicity test) resulting in an extended timeline. The company is waiting for confirmation on when the test will be started and how long it will take once started. Further, our primary lab is evaluating the handling of the test by the 3 rd party lab to mitigate any chance of further mold contamination on their end. Based on previous notes provided to our primary lab on the original contamination, it is believed that the first test may also have been due to mold due to several similarities. While it is no comfort to the current situation, the company was informed this isn’t an unusual issue with this particular MLA test. “Obviously we are extremely frustrated and disappointed by this second issue of contamination,” stated RemSleep CEO, Tom Wood. “The frustration is exasperated by not being able to ascertain the source or place where the contamination occurred. You do everything as advised in the handling of the sample products and still can’t be 100% sure. We took the additional steps in this latest sample and assume our partner lab will be able to further mitigate any potential issues on the contracted lab’s end and finally get the DeltaWave submitted for 510K clearance. On a positive note, the successful completion of all the remaining tests as well as no negative indications in the MLA test validate what we believed from the start of this very long process: the DeltaWave is safe as well as being effective. We were looking to expound upon the prior notice of RemSleep receiving the design patent for the DeltaWave along with successful completion of all tests. Now that we must repeat the MLA test again, this milestone accomplishment is clearly overshadowed. We are looking at formats for an investor call or interactive Q&A where we can go into more detail about how these events unfolded and answer investor questions. Further, we would like to provide more detail of the significance of the design patent and how it validates that the DeltaWave is truly unique and how the design aspects of the DeltaWave give us the results we have achieved. It is difficult to give depth into these issues in print. Once we get some of these questions on timeline answered, we will follow up with investors on a conference call or some type of interactive Q&A session format. It is frustrating, but shadows are not falling.” Finally, while the retesting timeline is being finalized, it is expected to the original compilation timeframe that was provided will be shortened as much of that work can be performed while the RMA test is being rerun. RemSleep appreciates the ongoing patience and understanding of investors and inherently understands the frustration and concerns of another setback. The company and will follow up accordingly in press releases, on the company Website: www.remsleep.com, and through the company Twitter feed: @RemsleepInc About RemSleep Holdings Inc. RemSleep Holdings Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive Sleep Apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of Sleep Apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the RemSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make the difference and improve the condition of those suffering from Sleep Apnea. www.remsleep.com https://twitter.com/RemsleepInc Forward-Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. No information in this press release should be construed as any indication whatsoever of the Company's future revenues, results of operations or stock price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation. Investor Relations Contact: Preya Narain info@preya.co Contact Details Preya Narain, Investor Relations info@preya.co Company Website https://remsleep.com/

May 31, 2023 05:08 PM Eastern Daylight Time

Syntekabio at The BIO International Convention, June 5-8

Syntekabio, Inc.

Syntekabio (226330.KQ), a global artificial intelligence (AI) drug discovery and development company, will exhibit at the BIO International Convention. The Convention showcases 4,000+ best and brightest biotechnology and pharma companies from 60+ countries, attracting 14,000+ attendees for intensive networking and partnership opportunities through 130+ interactive sessions across four days. Meet the Syntekabio team at our BOOTH #2785 at the BIO International Convention The Syntekabio team, led by CEO Jong-sun Jung, is looking forward to connecting with industry innovators and business leaders to build synergy through sharing expert insight and knowledge. Meet with us to learn about our latest one-stop AI drug discovery solution STB CLOUD, and envision how Syntekabio’s supercomputing-backed AI platforms can transform your business. WHAT: The BIO International Convention ( Booth #2785 near the BIO Lounge ) DATE: Monday, June 5 – Thursday, June 8, 2023 TIME: 8:00 am – 5:00 pm LOCATION: Boston Convention and Exhibition Center, 415 Summer St, Boston, MA 02210 (the Seaport District of Boston, MA) NOTES: Syntekabio CEO Jongsun Jung and his team of researchers are available onsite. To arrange a meeting, contact Ellie Woo at ellie.woo@syntekabio.com or +1 (917) 257-4533. For general inquires on our services, email Syntekabio’s New York office at admin.usa@syntekabio.com. ### About Syntekabio Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its US operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at STB CLOUD (syntekabio.com). Media Contact: Syntekabio USA Email: admin.usa@syntekabio.com Tel: +1 212-371-2544 Contact Details Syntekabio Ellie Woo +1 212-371-2544 admin.usa@syntekabio.com Company Website https://cloud.syntekabio.com/main

May 31, 2023 03:30 PM Eastern Daylight Time

Image

Algernon gets notice of allowance for patent to treat chronic kidney disease in Japan

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been granted a patent in Japan for its work around the Compositions and Methods for Treating Chronic Kidney Disease with drug NP-251 or Repirinast. Moreau telling Proactive this now repurposed drug was approved in the Japanese market for the treatment of asthma and this is now quite significant for its approval for use in the treatment of renal fibrosis or kidney disease. Repirinast has data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to medicine blood pressure drug telmisartan in a unilateral ureteral obstruction mouse model. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

May 31, 2023 01:54 PM Eastern Daylight Time

Video

Healthcare